Christophe Toukam Tchakoute1, Anneke C Hesseling2, Elvis B Kidzeru1, Hoyam Gamieldien3, Jo-Ann S Passmore4, Christine E Jones5, Clive M Gray6, Donald L Sodora7, Heather B Jaspan8. 1. Division of Immunology. 2. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town. 3. Division of Immunology Division of Medical Virology. 4. Division of Medical Virology National Health Laboratory Services, South Africa. 5. Institute of Infectious Disease and Molecular Medicine, Department of Clinical Laboratory Sciences, University of Cape Town Paediatric Infectious Diseases Research Group, St George's, University of London, United Kingdom. 6. Division of Immunology National Health Laboratory Services, South Africa. 7. Seattle Biomedical Research Institute, Washington. 8. Division of Immunology Seattle Biomedical Research Institute, Washington.
Abstract
BACKGROUND:BCG vaccination prevents disseminated tuberculosis in children, but it is contraindicated for persons with human immunodeficiency virus (HIV) infection because it can result in severe disease in this population. In tuberculosis-endemic regions, BCG vaccine is administered soon after birth, before in utero and peripartum HIV infection is excluded. We therefore assessed the immunogenicity of BCG vaccine in HIV-exposed infants who received BCG at birth or at 8 weeks of age. METHODS:HIV-exposed, uninfected infants were randomly assigned to receive BCG vaccination at birth (the early vaccination arm) or 8 weeks of age (the delayed vaccination arm). BCG-specific proliferative and intracellular cytokine responses were assessed in 28 infants per arm at 6, 8, and 14 weeks of life. RESULTS: There was no difference in BCG-specific T-cell proliferation between the study arms 6 weeks after vaccination. However, at 14 weeks of age, the frequency of interferon γ-expressing CD4(+) T cells and multifunctional BCG-specific responses in the delayed vaccinated arm were significantly higher than those in the early vaccination arm (P = .021 and P = .011, respectively). CONCLUSIONS: The immunogenicity of BCG vaccination in HIV-exposed, uninfected infants is not compromised when delayed until 8 weeks of age and results in robust BCG-specific T-cell responses at 14 weeks of age. These findings support further evaluation of this modified BCG vaccination strategy for HIV-exposed infants. CLINICAL TRIALS REGISTRATION: NCT02062580.
RCT Entities:
BACKGROUND: BCG vaccination prevents disseminated tuberculosis in children, but it is contraindicated for persons with human immunodeficiency virus (HIV) infection because it can result in severe disease in this population. In tuberculosis-endemic regions, BCG vaccine is administered soon after birth, before in utero and peripartum HIV infection is excluded. We therefore assessed the immunogenicity of BCG vaccine in HIV-exposed infants who received BCG at birth or at 8 weeks of age. METHODS:HIV-exposed, uninfected infants were randomly assigned to receive BCG vaccination at birth (the early vaccination arm) or 8 weeks of age (the delayed vaccination arm). BCG-specific proliferative and intracellular cytokine responses were assessed in 28 infants per arm at 6, 8, and 14 weeks of life. RESULTS: There was no difference in BCG-specific T-cell proliferation between the study arms 6 weeks after vaccination. However, at 14 weeks of age, the frequency of interferon γ-expressing CD4(+) T cells and multifunctional BCG-specific responses in the delayed vaccinated arm were significantly higher than those in the early vaccination arm (P = .021 and P = .011, respectively). CONCLUSIONS: The immunogenicity of BCG vaccination in HIV-exposed, uninfected infants is not compromised when delayed until 8 weeks of age and results in robust BCG-specific T-cell responses at 14 weeks of age. These findings support further evaluation of this modified BCG vaccination strategy for HIV-exposed infants. CLINICAL TRIALS REGISTRATION: NCT02062580.
Authors: Elvis B Kidzeru; Anneke C Hesseling; Jo-Ann S Passmore; Landon Myer; Hoyam Gamieldien; Christophe Toukam Tchakoute; Clive M Gray; Donald L Sodora; Heather B Jaspan Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: A C Hesseling; H Rabie; B J Marais; M Manders; M Lips; H S Schaaf; R P Gie; M F Cotton; P D van Helden; R M Warren; N Beyers Journal: Clin Infect Dis Date: 2006-01-11 Impact factor: 9.079
Authors: Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet Journal: Proc Natl Acad Sci U S A Date: 2009-02-02 Impact factor: 11.205
Authors: Annelies Van Rie; Shabir A Madhi; Jayvant R Heera; Stephen Meddows-Taylor; Aaron M Wendelboe; Fiona Anthony; Avy Violari; Caroline T Tiemessen Journal: Clin Vaccine Immunol Date: 2006-02
Authors: Anna K Blakney; Christophe Toukam Tchakoute; Anneke C Hesseling; Elvis B Kidzeru; Christine E Jones; Jo-Ann S Passmore; Donald L Sodora; Clive M Gray; Heather B Jaspan Journal: Vaccine Date: 2015-08-07 Impact factor: 3.641
Authors: T N Nissen; N M Birk; B A Blok; R J W Arts; A Andersen; J Kjærgaard; L M Thøstesen; T Hoffmann; D L Jeppesen; S D Nielsen; P-E Kofoed; L G Stensballe; P Aaby; M Ruhwald; M G Netea; C S Benn; O Pryds Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-10 Impact factor: 3.267